ArticleBMC research notes2025
Antiviral activity of silver nanoparticles against H1N1 influenza virus.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Features and In Vitro Assessment of Antiviral Activity of Organic Coatings Doped with Silver-Based Compounds Against Human Coronavirus.International journal of molecular sciences · 2025Article
- Computational screening of antiviral candidates for Monkeypox virus DNA polymerase and A42R protein.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfluenza virus is a significant cause of annual global respiratory disease and death. According to the limited availability of effective drugs and vaccines, innovative antivirals are currently being investigated as possible strategies to contain the spread of infectious agents. Among the various types of nanoparticles, silver nanoparticles (Ag-NPs) have attracted great interest due to their exceptional physicochemical properties. This study aims to investigate the antiviral activity of Ag-NPs against the influenza A virus (IAV)/H1N1.
methodsThe MTT assay was used to determine the possible cytotoxicity of the Ag-NPs. Madin-Darby canine kidney (MDCK) cells were exposed to Ag-NPs extract in conjunction with 100 cell culture infectious dose 50% (CCID50) of virus administered at time intervals during the infection process. The antiviral activity of the extract was evaluated under pre-treatment, post-treatment, and simultaneous assay. Viral titer reduction was assayed using hemagglutination (HA) and CCID50 assays. Viral RNA relative quantification by real-time Polymerase Chain Reaction approach was performed in each experimental condition.
resultsThe study yielded significant findings regarding the inhibitory effects of Ag-NPs on the IAV/H1N1. Silver nanoparticles showed dose-dependent inhibition of the virus, with the strongest effect observed when administered simultaneously with the virus which the virus titer exhibited a substantial decrease from 5 Log10 in the control group to 1 Log10 in the initial samples, further reducing to 2 Log10 per milliliter at lower concentrations. Notably, Ag-NPs demonstrated a greater reduction in virus titer during the simultaneous stage, showing a statistically significant difference (P < 0.05) between the control and experimental groups). The reduction in viral titer was also evident in both pre- and post-inoculation stages, although the effects were different.
conclusionSilver nanoparticles possess inhibitory effects on the growth of the IAV/H1N1, with a significant reduction in virus titer. These findings suggest the potential of Ag-NPs as effective antiviral agents and highlight opportunities for further research and potential clinical applications in combating IAV (H1N1) infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.